-
-
-
-
-
-
-
Canaccord Starts Structure Therapeutics (GPCR) at Buy
-
-
-
-
-
-
-
Citizens Reiterates Market Outperform Rating on Structure Therapeutics (GPCR)
-
-
-
-
-
-
-
Structure Therapeutics (GPCR) PT Lowered to $113 at Citizens Ahead of Readouts
-
-
-
-
-
-
-
Structure Therapeutics subsidiary licenses patents to Genentech for $100M
-
-
-
-
-
-
-
After-hours movers: NVIDIA, Toll Brothers, and more
-
-
-
-
-
-
-
BMO Capital Reiterates Outperform Rating on Structure Therapeutics (GPCR)
-
-
-
-
-
-
-
FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
-
460,867 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

